The U.S. Food and Drug Administration approved gedatolisib (Revtorpyk) on July 14, 2026, for the treatment of patients with hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer who do not have a PIK3CA mutation, following progression on at least one line of endocrine therapy in the metastatic setting. Developed by Celcuity Inc., a Minneapolis-based biotechnology company, Revtorpyk is the first and only FDA-approved therapy to inhibit all four class I PI3K isoforms and both mTOR complexes simultaneously.
The approval addresses one of the most significant unmet needs in breast cancer treatment: the approximately 60 percent of second-line HR+/HER2- metastatic breast cancer patients who do not have a PIK3CA mutation and for whom no therapy in this mechanistic class was previously approved. An estimated 37,000 women per year in the United States fall into this category, according to Celcuity's announcement.
Why This Matters
Breast cancer is the most commonly diagnosed cancer among American women, with hormone receptor-positive, HER2-negative disease accounting for the largest share of metastatic breast cancer cases. When these cancers progress after initial endocrine therapy, oncologists have needed to choose from a limited set of options. The PI3K/mTOR signaling pathway is an important driver of cancer cell growth in HR+/HER2- disease, but previous PI3K inhibitors approved in this setting, such as alpelisib, were effective only in patients whose tumors carry specific PIK3CA mutations.
That restriction left patients without a PIK3CA mutation without a targeted option in this pathway. Gedatolisib was designed to work differently, by blocking the entire PI3K pathway rather than a single mutation-driven enzyme. The result is the first targeted therapy in this mechanistic class available to the broader population of HR+/HER2- patients regardless of their PIK3CA mutational status.
What We Know So Far
The FDA approval is based on results from the Phase 3 VIKTORIA-1 trial, which evaluated gedatolisib in combination with the endocrine therapy fulvestrant, with or without the CDK4/6 inhibitor palbociclib, compared to fulvestrant alone in patients with PIK3CA wild-type advanced or metastatic breast cancer. The trial enrolled patients who had previously received endocrine therapy in the metastatic setting.
The results were striking. Gedatolisib combined with palbociclib and fulvestrant reduced the risk of disease progression or death by 76 percent compared to fulvestrant alone in the PIK3CA wild-type population. The combination of gedatolisib with fulvestrant without palbociclib reduced that risk by 67 percent. These numbers represent among the strongest progression-free survival results reported in this patient population in the second-line metastatic setting.
Celcuity has also announced plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026 for gedatolisib in patients who do have a PIK3CA mutation, based on results from the mutant cohort of VIKTORIA-1 presented at the 2026 ASCO Annual Meeting. If that application succeeds, gedatolisib could eventually cover both the mutant and wild-type populations, making it a broadly applicable option in HR+/HER2- metastatic breast cancer.
Where the Impact Is Highest
The population most directly affected by this approval is women with HR+/HER2- metastatic breast cancer who have already received CDK4/6 inhibitor-based therapy with endocrine therapy as first-line treatment and whose disease has progressed. This group numbers in the tens of thousands annually in the United States. Large breast cancer centers in cities including Houston, New York, Chicago, Boston, Los Angeles, and Atlanta will begin integrating gedatolisib into their formularies and clinical protocols.
Community oncology practices, which treat the majority of breast cancer patients in the United States, will need time to update protocols and navigate insurance coverage for a newly approved branded therapy. Access in community settings typically follows within weeks to months after a major center adoption.
What Doctors and Experts Say
CancerNetwork's coverage quoted an oncologist involved in the trial as saying: "In my opinion, I think this could be immediately practice changing. The progression-free survival data that we're seeing in both the PIK3CA wild-type and PIK3CA-mutant populations was consistently better than in the control arm."
Celcuity described Revtorpyk as the company's first FDA-approved product and characterized gedatolisib's mechanism, a comprehensive blockade of the PI3K/AKT/mTOR pathway rather than a single node, as clinically differentiated from prior approvals in this pathway. The dual inhibition of both mTORC1 and mTORC2 is considered significant because mTORC2 drives feedback resistance mechanisms that can limit the effectiveness of mTORC1-only inhibitors.
What the Evidence Shows and What It Does Not
The VIKTORIA-1 trial is a Phase 3 randomized controlled trial, which places the evidence at the highest standard for oncology drug approval. The 76 percent and 67 percent reductions in progression risk are the primary efficacy findings. Overall survival data from VIKTORIA-1 are not yet mature, meaning the question of whether the progression-free survival benefit translates to longer life expectancy has not been definitively answered.
Like all PI3K inhibitors, gedatolisib carries a risk of metabolic side effects. The class is associated with hyperglycemia, rash, diarrhea, and fatigue. The specific safety profile for gedatolisib as detailed in the FDA's full prescribing information will guide clinicians on monitoring and management. Patients with pre-existing diabetes or metabolic conditions should discuss these risks with their oncologist before beginning treatment.
MedicalDaily Evidence Check
The VIKTORIA-1 trial is a Phase 3 randomized controlled trial enrolling patients with PIK3CA wild-type HR+/HER2- locally advanced or metastatic breast cancer who had progressed on endocrine therapy, with data presented at the 2026 ASCO Annual Meeting.
The study found that gedatolisib combined with palbociclib and fulvestrant reduced the risk of disease progression or death by 76 percent compared to fulvestrant alone, while gedatolisib combined with fulvestrant without palbociclib reduced that risk by 67 percent.
What the trial did not prove is an overall survival benefit, as OS data are not yet mature and the question of whether the progression-free survival gains translate to longer life expectancy has not been definitively answered. Readers should know that this is the first FDA-approved therapy specifically indicated for the PIK3CA wild-type subgroup, and that PIK3CA testing through tumor molecular profiling is required to confirm that a patient qualifies for this treatment.
Who Faces the Greatest Risk Without This Option
Women with HR+/HER2- metastatic breast cancer whose tumors have been tested and confirmed as PIK3CA wild-type, who have already progressed on a CDK4/6 inhibitor plus endocrine therapy regimen, previously had no targeted option in the PI3K/mTOR pathway. That population, approximately 37,000 U.S. women per year according to Celcuity's estimates, is now the primary beneficiary of this approval.
Patients who have not yet been tested for PIK3CA mutational status should request that testing as part of routine molecular profiling of their breast cancer, which is now standard of care at major cancer centers.
Symptoms and Warning Signs to Watch For
Metastatic breast cancer may present with new or worsening bone pain, unexplained fatigue, shortness of breath, persistent cough, abdominal pain, jaundice, neurological symptoms including headache or vision changes, or enlarging lymph nodes. Patients already in treatment for HR+/HER2- metastatic disease should watch for signs of disease progression, including worsening pain, new lesions on imaging, or rising tumor markers, and communicate these promptly to their oncologist.
Side effects specific to PI3K/mTOR pathway inhibitors include elevated blood sugar, skin rash, diarrhea, nausea, and fatigue. Patients on gedatolisib should have regular blood glucose monitoring and communicate any rash or gastrointestinal symptoms to their care team promptly.
What You Can Do Now
Patients currently on treatment for HR+/HER2- metastatic breast cancer should ask their oncologist whether their tumor has been tested for PIK3CA mutational status and, if confirmed wild-type, whether gedatolisib is appropriate at their current treatment stage. Patients who have progressed on prior endocrine-based therapy and have not yet received second-line treatment should ask whether VIKTORIA-1 data and the new FDA approval are relevant to their situation.
Newly diagnosed metastatic breast cancer patients should ask their oncologist to perform comprehensive molecular profiling at diagnosis, including PIK3CA mutation testing, to ensure they have the information needed to access all relevant treatment options as their disease evolves.
Cost and Access: What Patients Should Know
Revtorpyk is a newly approved branded oncology therapy and will carry a premium price. Coverage by commercial insurance and Medicare Part D will be determined by individual plan formularies. Celcuity is expected to launch patient assistance and copay support programs, as is standard for new oncology approvals. Patients without coverage should ask their cancer center's financial navigator or social worker for assistance and can contact the Patient Advocate Foundation for help navigating coverage appeals and assistance programs.
What Happens Next
Celcuity plans to file a supplemental NDA for gedatolisib in the PIK3CA-mutant population in the third quarter of 2026, which would potentially expand the drug's indicated population to include both the wild-type and mutant subgroups. The ongoing Phase 3 VIKTORIA-2 trial is evaluating gedatolisib in earlier treatment settings. Overall survival data from VIKTORIA-1 will mature over time and are expected to be presented at future oncology conferences. MedicalDaily will track the supplemental NDA timeline and additional data releases.
The Bottom Line
The FDA approval of gedatolisib (Revtorpyk) on July 14, 2026, closes a long-standing gap for tens of thousands of American women with HR+/HER2- metastatic breast cancer who previously had no targeted option in the PI3K/mTOR pathway because their tumors lack a PIK3CA mutation. The Phase 3 trial results are among the strongest reported in this setting. The most important immediate step for eligible patients is confirming PIK3CA mutational status and discussing this approval with their oncologist.
